Skip to content
Buy This GLP
← Research
Evidence

Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key

Part D still cannot cover a drug for weight alone, but sleep apnea with obesity is a covered use. A sleep study supports the diagnosis, and the plan reviews whether the prescription meets its requirements.

Editorial profile: Neil SandersBuy This GLP Editorial Team6 min read
What the claim rests onSleep studyAHI 15 or moreObesityBMI 30 or morePrescriptionfor sleep apneaPart D claimplan reviewTrial thresholds shown. Your plan sets its approval requirements.

Medicare Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. The plan may require prior authorization or a formulary exception. CMS directs these requests through Part D [8]. The trials behind the label required 15 or more breathing events an hour on a sleep study [5].

Basic Part D generally excludes drugs used solely for weight loss [3]. Our guide to Medicare GLP-1 coverage explains the separate Bridge program for eligible weight-management prescriptions. CMS says Zepbound prescribed for sleep apnea goes through the Part D plan instead [8].

Why sleep apnea is a different claim

A claim is judged by its use, not its molecule. Zepbound has two uses on its label. One is weight reduction, and the other is moderate to severe obstructive sleep apnea in adults with obesity [5]. The second is not a weight-loss use.

A 2026 study used 2023 and 2024 claims for adults continuously enrolled in Medicare fee-for-service Parts A, B, and D [2]. It listed four covered GLP-1 uses [2]. Two are type 2 diabetes and heart disease with overweight or obesity. The others are sleep apnea with obesity and a fatty liver disease [2]. About 1.2 million beneficiaries had obesity without one of the covered diagnoses under the study’s definition [2].

The comparison of Zepbound and Mounjaro explains why the branded prescription matters even though both contain tirzepatide. For Part D, confirm the indication on the prescription and the plan’s requirements.

The diagnosis has to be on paper

The label’s trials defined moderate to severe apnea by a number. They required an apnea-hypopnea index of 15 or more events an hour [5]. That was measured by polysomnogram, an overnight sleep study [5]. The trials also required a BMI of 30 or more [5]. People with type 2 diabetes were excluded [5].

The index itself depends on a scoring rule. A hypopnea can be counted at a 4% drop in oxygen, or at a 3% drop or an arousal [4]. One study rescored a sample of 2,057 people both ways [4]. Under the stricter 4% rule, 60% moved to a milder grade or lost the diagnosis [4].

That shift changed who appeared eligible for tirzepatide under the study’s criteria. Of those eligible under the 3% oxygen drop or arousal rule, 180 people (35%) no longer qualified under the 4% rule [4]. Women were reclassified more often than men [4]. The sleep report is therefore the document to read first.

What the trials measured

SURMOUNT-OSA consisted of two 52-week trials [1]. One enrolled people not using positive airway pressure (PAP), and the other enrolled people already using it. Starting indexes averaged 51.5 and 49.5 events an hour [1].

The sleep apnea trial guide explains how the trials handled breathing-device use. At 52 weeks, the trial without PAP found declines of 25.3 events per hour with tirzepatide and 5.3 with placebo [1]. Among people already using PAP at enrollment, the index fell 29.3 and 5.5 events per hour, respectively [1]. That trial asked participants to pause PAP for seven days before the endpoint sleep study [5].

Eligible is not the same as filled

Among 16,474,786 Medicare fee-for-service beneficiaries with Part D, 35.1% had a covered GLP-1 condition [2]. Of those, 16.5% had a claim [2]. The authors say eligibility alone may not become treatment without addressing affordability [2].

The study measured claims across multiple covered GLP-1 uses in fee-for-service Medicare [2]. It did not report that 16.5% of people with sleep apnea filled Zepbound. Use the insurance worksheet to record what your plan says about coverage for your prescription. Ask about any authorization or exception before assuming it will be covered.

What it costs without coverage

The label lists 10 mg and 15 mg weekly as maintenance doses for sleep apnea [5]. The following prices are from LillyDirect as checked November 14, 2026.

LillyDirect publishes a self-pay price for each strength. At 10 mg and 15 mg it reads “Starting at $449/month” “when you refill within 45 days” [7]. Miss that window and the footnote applies: “$699 for 10mg” and “$699 for 15mg” [7]. A month is 28 days and one KwikPen [7].

The Zepbound savings guide for Medicare explains how to tell the commercial savings card from the separate self-pay program. Lilly’s commercial card excludes Medicare enrollees [6]. Check the self-pay terms for the exact product before filling.

Frequently asked

Is Zepbound covered by Medicare for sleep apnea?
Part D can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity. Check the plan for formulary status and any prior authorization or exception requirements. The Medicare GLP-1 Bridge covers qualifying weight-management prescriptions through a separate process.
How much does Zepbound for sleep apnea cost without insurance?
The sleep apnea doses are 10 mg or 15 mg. Lilly's own pharmacy lists the KwikPen at $449 a month at those doses when refilled within 45 days, and $699 otherwise. A month is 28 days and one pen.
What does a Zepbound sleep apnea insurance claim need?
A prescription written for sleep apnea, and a diagnosis of moderate to severe apnea with obesity. The trials behind the label used an apnea-hypopnea index of 15 or more on an overnight sleep study and a BMI of 30 or more.
Can I use the Zepbound savings card on Medicare?
No. Lilly's terms for the $25 card read "Governmental beneficiaries excluded."

Sources

  1. [1] Malhotra A, Grunstein RR, Fietze I, et al. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity The New England Journal of Medicine. PMID 38912654
  2. [2] Kim S, Barthel A, Smurzynski M, MacEwan J (2026). Prevalence of Obesity and Related Conditions and GLP-1 Use in Medicare Fee-for-Service Beneficiaries Diabetes, Obesity & Metabolism. PMID 42348175
  3. [3] Hernandez I, Wright DR, Guo J, Shrank WH (2024). Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform Journal of General Internal Medicine. PMID 37715099
  4. [4] Oo HH, Wu ZH, Liu D, Lenka J, Maheshwari N, Salmon A (2026). Varying Hypopnea Definitions and Treatment Eligibility in Obstructive Sleep Apnea Sleep & Breathing. PMID 41925927
  5. [5] Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — prescribing information, sections 1, 2 and 14.2 DailyMed, U.S. National Library of Medicine. Source
  6. [6] Eli Lilly and Company (2026). Zepbound savings and insurance options Lilly. Source
  7. [7] Eli Lilly and Company (2026). Zepbound on LillyDirect: KwikPen self-pay prices, checked November 14, 2026 LillyDirect. Source
  8. [8] Centers for Medicare & Medicaid Services (2026). Medicare GLP-1 Bridge: Information for Part D Plans CMS. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence